January 9, 2018 / 12:22 PM / in 10 minutes BRIEF-FDA Clears Pluristem’s Expanded Access Program To Initiate Treatments Of Critical Limb Ischemia Reuters Staff 1 Min Read 
Jan 9 (Reuters) - Pluristem Therapeutics Inc: 
* PLURISTEM THERAPEUTICS - U.S. ‍FDA CLEARED CO‘S EXPANDED ACCESS PROGRAM FOR USE OF PLX-PAD CELL TREATMENT IN PATIENTS WITH CRITICAL LIMB ISCHEMIA​ 
* FDA CLEARS PLURISTEM’S EXPANDED ACCESS PROGRAM TO INITIATE TREATMENTS OF CRITICAL LIMB ISCHEMIA OUTSIDE OF ONGOING PHASE III STUDY Source text for Eikon: Further company coverage: